Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

the Geriatric Depression Scale (GDS), first created by Yesavage et al., has been tested and used extensively with the older population. It is a brief questionnaire in which participants are asked ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

Included studies were synthesised using meta-analyses. Results A total of 24 included studies provided data on 2907 participants. The Center of Epidemiological Studies-Depression Scale (CESD) ...

Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 20% aftermarket. The company said the ...

The Alzheimer's Association revised the diagnostic criteria for Alzheimer disease (AD) and ADRD for clinicians in primary and specialty care.

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

“If you’re comfortable talking about it with trusted friends or family members, getting a referral from someone you trust and ...

Third, depression diagnosis was largely inconsistent. Most studies relied on rating scales, such as the Center for Epidemiological Studies Depression (CES-D) Scale, the Beck Depression Inventory (BDI) ...

The primary efficacy outcome was the response to treatment, which was defined as an at least 50% decrease on a depression scale from baseline to the end of treatment. Secondary efficacy outcomes ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...